JP2017149720A5 - - Google Patents

Download PDF

Info

Publication number
JP2017149720A5
JP2017149720A5 JP2017047055A JP2017047055A JP2017149720A5 JP 2017149720 A5 JP2017149720 A5 JP 2017149720A5 JP 2017047055 A JP2017047055 A JP 2017047055A JP 2017047055 A JP2017047055 A JP 2017047055A JP 2017149720 A5 JP2017149720 A5 JP 2017149720A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
amino acid
constant region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017047055A
Other languages
English (en)
Japanese (ja)
Other versions
JP6513728B2 (ja
JP2017149720A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017149720A publication Critical patent/JP2017149720A/ja
Publication of JP2017149720A5 publication Critical patent/JP2017149720A5/ja
Application granted granted Critical
Publication of JP6513728B2 publication Critical patent/JP6513728B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017047055A 2011-11-23 2017-03-13 Her3に特異的な結合分子及びそれらの使用 Active JP6513728B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161563092P 2011-11-23 2011-11-23
US61/563,092 2011-11-23
US201261656670P 2012-06-07 2012-06-07
US61/656,670 2012-06-07
US201261722558P 2012-11-05 2012-11-05
US61/722,558 2012-11-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014543533A Division JP6180425B2 (ja) 2011-11-23 2012-11-20 Her3に特異的な結合分子及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2017149720A JP2017149720A (ja) 2017-08-31
JP2017149720A5 true JP2017149720A5 (enExample) 2017-10-26
JP6513728B2 JP6513728B2 (ja) 2019-05-15

Family

ID=48470246

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014543533A Active JP6180425B2 (ja) 2011-11-23 2012-11-20 Her3に特異的な結合分子及びそれらの使用
JP2017047055A Active JP6513728B2 (ja) 2011-11-23 2017-03-13 Her3に特異的な結合分子及びそれらの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014543533A Active JP6180425B2 (ja) 2011-11-23 2012-11-20 Her3に特異的な結合分子及びそれらの使用

Country Status (17)

Country Link
US (3) US9220775B2 (enExample)
EP (2) EP3608340A1 (enExample)
JP (2) JP6180425B2 (enExample)
KR (1) KR102080535B1 (enExample)
CN (2) CN104093743B (enExample)
AU (1) AU2012340766B2 (enExample)
BR (1) BR112014012539B1 (enExample)
CA (1) CA2856297C (enExample)
CO (1) CO7051008A2 (enExample)
DK (1) DK2797957T3 (enExample)
ES (1) ES2745684T3 (enExample)
IL (1) IL232726B2 (enExample)
MX (1) MX350957B (enExample)
RU (1) RU2620068C2 (enExample)
SG (1) SG11201402536PA (enExample)
WO (1) WO2013078191A1 (enExample)
ZA (1) ZA201403570B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
CN108341873B (zh) * 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015048008A2 (en) * 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
SG10201913289TA (en) 2014-02-28 2020-02-27 Merus Nv Antibody that binds erbb-2 and erbb-3
NZ724013A (en) 2014-02-28 2019-11-29 Merus Nv Antibodies that bind egfr and erbb3
RU2683276C2 (ru) * 2014-04-04 2019-03-27 Астразенека Аб Комбинация ингибитора EGFR и ингибитора MEK для применения в лечении рака, вызванного мутировавшим NRAS
WO2015157634A1 (en) * 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
US20170190788A1 (en) * 2014-09-11 2017-07-06 Bulldog Pharmaceuticals, Inc. Uses of anti-her3 antibodies for treating cancer
US20180171027A1 (en) * 2015-04-17 2018-06-21 Celldex Therapeutics, Inc. Biomarkers Related to Treatment of Cancer with HER3 and EGFR Inhibitors
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Her3抗體
MD3365373T2 (ro) 2015-10-23 2021-08-31 Merus Nv Molecule de legare care inhibă dezvoltarea cancerului
WO2017100642A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
MX2018011054A (es) 2016-03-15 2019-01-21 Merrimack Pharmaceuticals Inc Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
KR101796684B1 (ko) 2016-05-19 2017-11-10 건국대학교 산학협력단 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
EP3590534A4 (en) * 2017-02-28 2020-12-23 Kinki University METHOD OF TREATMENT OF EGFR-TKI-RESISTANT NON-SMALL-CELL LUNG CANCER BY ADMINISTRATION OF ANTI-HER3-DRUG ANTIBODY CONJUGATE
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
BR112019024230A2 (pt) 2017-05-17 2020-06-09 Merus N.V. combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama
HUE071182T2 (hu) 2017-08-09 2025-08-28 Merus Nv EGFR és CMET kötõ antitestek
CN110724194B (zh) * 2018-07-17 2021-03-19 上海生物制品研究所有限责任公司 抗her3人源化单克隆抗体及其制剂
EP3849538A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
CN110760003A (zh) * 2019-09-10 2020-02-07 广东药科大学 一种抗her3单链抗体的制备方法
EP4044809A4 (en) * 2019-11-12 2023-11-29 University of Virginia Patent Foundation DESIGN OF AN OPTICAL ENZYME CUTTER FOR AGE-RELATED MACULAR DEGENERATION
AU2023228226A1 (en) * 2022-03-03 2024-10-03 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Her3 binding protein and use thereof
AU2023362061A1 (en) * 2022-10-19 2025-04-24 Multitude Therapeutics Inc. Antibody-drug conjugate, preparation method therefor and use thereof in resisting tumors

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3546806C2 (enExample) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
JP3925943B2 (ja) * 1996-03-27 2007-06-06 ジェネンテック インコーポレーテッド ErbB3抗体
US5804968A (en) 1997-01-29 1998-09-08 Picker International, Inc. Gradient coils with reduced eddy currents
US20030105057A1 (en) 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
PT998486E (pt) 1997-06-13 2007-08-21 Genentech Inc ''recuperação de proteínas por cromatografia seguida de filtração numa camada carregada''
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
ES2329437T3 (es) 1999-06-25 2009-11-26 Genentech, Inc. Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US7390632B2 (en) 1999-09-30 2008-06-24 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CN109395082A (zh) 2000-05-19 2019-03-01 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
US20040116330A1 (en) 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
WO2002087619A1 (en) 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
US7638302B2 (en) 2001-05-31 2009-12-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
IL158969A0 (en) 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
RU2335507C2 (ru) 2001-06-13 2008-10-10 Генмаб А/С Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор
JP2005500034A (ja) 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
AU2002326531A1 (en) 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
AU2003218600C1 (en) 2002-03-26 2009-12-17 Zensun (Shanghai) Science & Technology Co., Ltd. ERBB3 based methods and compositions for treating neoplasms
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
KR100788093B1 (ko) 2002-04-26 2007-12-21 제넨테크, 인크. 단백질의 비친화성 정제
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229293A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US20040229299A1 (en) 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
AT413486B (de) 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
DK2263691T3 (da) * 2002-07-15 2012-10-22 Hoffmann La Roche Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4)
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2004012769A1 (en) 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
JPWO2004026341A1 (ja) 2002-09-19 2006-01-12 株式会社オリエントキャンサーセラピー ガンの免疫治療剤
CN102875680B (zh) 2002-11-07 2015-04-22 伊谬诺金公司 抗-cd33抗体和使用其治疗急性髓性白血病的方法
EP1585768A2 (en) 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1597350B1 (en) 2003-02-27 2015-04-08 Yeda Research And Development Co., Ltd. Nucleic acid molecules, and compositions containing same useful for treating and detecting influenza virus infection
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン,エルエルシー 組換えil−9抗体およびその使用
TW568408U (en) 2003-05-14 2003-12-21 High Tech Comp Corp Slide structure
BRPI0411250A (pt) 2003-06-09 2006-08-29 Samuel Waksal método de inibição de receptor tirosina cinase com um antagonista extracelular e um antagonista intracellular
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
HUE029951T2 (en) 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
US20060204966A1 (en) 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
CA2544863A1 (en) 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
JP4969440B2 (ja) 2004-04-08 2012-07-04 デビッド, ビー. エイガス, 疼痛治療のためのErbBアンタゴニスト
BRPI0510716A (pt) 2004-05-05 2007-11-20 Merrimack Pharmaceuticals Inc uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
WO2006024497A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
EP1807106A2 (en) 2004-10-05 2007-07-18 Oregon Health and Science University Compositions and methods for treating disease
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
CN101163503B (zh) 2005-02-23 2013-05-08 健泰科生物技术公司 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
EP1856158A4 (en) 2005-03-07 2010-07-28 Targeted Molecular Diagnostics TYROSINE KINASE INHIBITOR COMPOSITIONS AND METHODS OF MAKING SAME AND USE THEREOF IN TREATING DISEASE
WO2006133460A2 (en) 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
CN101309933A (zh) * 2005-09-07 2008-11-19 米迪缪尼有限公司 毒素偶联的Eph受体抗体
JP2009506790A (ja) 2005-09-07 2009-02-19 メディミューン,エルエルシー 毒素とコンジュゲートしたeph受容体抗体
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
EP1968579A1 (en) 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7897723B2 (en) 2006-04-07 2011-03-01 Københavns Universitet ErbB receptor-derived peptide fragments
WO2007122369A2 (en) 2006-04-13 2007-11-01 Oncomethylome Sciences Sa Novel tumour suppressor
EP2091975A4 (en) 2006-11-21 2013-05-22 Univ California ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE
AU2007324868B2 (en) 2006-11-28 2014-03-20 Daiichi Sankyo Europe Gmbh Activated HER3 as a marker for predicting therapeutic efficacy
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
WO2008081331A2 (en) 2006-12-29 2008-07-10 Sinomab Bioscience Limited Enhancing the level of antibody expression by framework re-engineering
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
JP5564266B2 (ja) 2007-02-16 2014-07-30 メリマック ファーマシューティカルズ インコーポレーティッド Erbb3に対する抗体およびその使用
TWI352199B (en) 2007-03-02 2011-11-11 Genentech Inc Predicting response to a her inhibitor
WO2008112129A2 (en) 2007-03-09 2008-09-18 Geron Corporation Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors
CN101802015B (zh) 2007-03-29 2015-05-06 根马布股份公司 双特异性抗体及其制造方法
JP5926487B2 (ja) 2007-04-13 2016-05-25 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド ErbB療法に耐性である癌を治療するための方法
US20090258005A1 (en) 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
EP2205277B1 (en) 2007-10-22 2017-07-26 Genmab A/S Novel antibody therapies
CA2706425A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
EP2275431A3 (en) 2008-01-18 2011-05-25 Bio-Rad Laboratories, Inc. Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
US20110027296A1 (en) 2008-04-09 2011-02-03 Universidad De Barcelona Antibodies for treating cancer
ES2525065T3 (es) 2008-04-11 2014-12-17 Merrimack Pharmaceuticals, Inc. Ligadores de seroalbúmina humana y sus conjugados
WO2009157919A1 (en) 2008-06-23 2009-12-30 Tumor Biology Investment Group, Inc. SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER
EP2138511A1 (en) 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
EP2159836B1 (en) 2008-08-25 2017-05-31 Soitec Stiffening layers for the relaxation of strained layers
NZ592326A (en) 2008-11-07 2013-01-25 Enzon Pharmaceuticals Inc Erbb-3 (her3)-selective combination therapy
SG171764A1 (en) 2008-12-16 2011-07-28 Millipore Corp Purification of proteins
ES2434017T3 (es) 2009-02-24 2013-12-13 F. Hoffmann-La Roche Ag Utilización del s-ErbB-3 como marcador de cáncer
JP5624114B2 (ja) 2009-03-20 2014-11-12 ジェネンテック, インコーポレイテッド 抗her抗体
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP2012525432A (ja) 2009-04-29 2012-10-22 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー ヘレグリン共役型her3と免疫反応性の改善された抗体
US20120107270A1 (en) 2009-06-30 2012-05-03 Manuela Kaspar Immunocytokines In Combination With Anti-ErbB Antibodies For The Treatment Of Cancer
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
AU2010303443A1 (en) * 2009-10-09 2012-04-19 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-Her 3 antibodies
JP2013507926A (ja) 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド IGF−1R及びErbB3シグナル伝達を標的とする二重特異的結合剤及びその使用
TWI630916B (zh) 2009-11-13 2018-08-01 第一三共歐洲公司 供治療或預防人表皮生長因子受體-3(her-3)相關疾病之藥料和方法
RS54795B1 (sr) * 2009-12-22 2016-10-31 Roche Glycart Ag Anti-her3 antitela i njihova korišćenja
EP2544680B1 (en) 2010-03-11 2015-01-14 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative breast cancer
RU2568051C2 (ru) 2010-04-09 2015-11-10 Авео Фармасьютикалз, Инк. АНТИТЕЛА К ErbB3
WO2011153383A1 (en) 2010-06-04 2011-12-08 Bipar Science, Inc. Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
EP2601220A2 (en) 2010-08-06 2013-06-12 U3 Pharma GmbH Use of her3 binding agents in prostate treatment
HUE031855T2 (en) * 2010-08-20 2017-08-28 Novartis Ag Anti-epidermal growth factor receptor 3 (HER3) antibodies
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
JP5995851B2 (ja) 2010-10-18 2016-09-21 メディアファーマ エス. アール. エル.Mediapharma S. R. L. ErbB3結合抗体
WO2012059858A1 (en) 2010-11-01 2012-05-10 Symphogen A/S Anti-her3 antibodies and compositions
AU2012229062A1 (en) 2011-03-15 2013-04-11 Merrimack Pharmaceuticals, Inc. Overcoming resistance to ErbB pathway inhibitors
JPWO2012176779A1 (ja) 2011-06-20 2015-02-23 協和発酵キリン株式会社 抗erbB3抗体
MX357391B (es) 2011-09-30 2018-07-06 Regeneron Pharma Anticuerpos anti-erbb3 y usos de los mismos.
US9637543B2 (en) 2011-11-09 2017-05-02 The Uab Research Foundation HER3 antibodies and uses thereof
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
HK1206645A1 (en) 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Ionizable cationic lipids
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
WO2015048008A2 (en) * 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
US20170190788A1 (en) 2014-09-11 2017-07-06 Bulldog Pharmaceuticals, Inc. Uses of anti-her3 antibodies for treating cancer
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Similar Documents

Publication Publication Date Title
JP2017149720A5 (enExample)
JP2015506912A5 (enExample)
KR102078292B1 (ko) 신규한 항 c-Met 항체 및 이의 용도
RU2014120757A (ru) Связывающие молекулы, специфичные по отношению к her3, и их применения
CN103260646B (zh) Notum蛋白调节剂和使用方法
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
JP2023525827A (ja) 抗cd73抗体およびその使用
JP2020514277A5 (enExample)
KR20160070191A (ko) 신규한 항-클라우딘 항체 및 사용 방법
JP2019532619A5 (enExample)
JP2016526904A5 (enExample)
JP2017535257A5 (enExample)
HK1215035A1 (zh) 人源化抗cd134(ox40)抗體及其應用
JP2018502050A5 (enExample)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2017512765A5 (enExample)
JP2017535257A (ja) 免疫応答およびがん治療の増強に使用するための組成物および方法
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
CN106459212A (zh) 结合erbb‑2和erbb‑3的抗体
CN118126180A (zh) 抗cd3抗体和包含所述抗体的分子
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
WO2014185704A1 (ko) Her2에 특이적으로 결합하는 항체
JP7328324B2 (ja) Tim-3に対する抗体およびその使用
JP2020521504A (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
CA3193584A1 (en) Nectin-4 antibodies and uses thereof